All In Biotech

BLA 761286 · Ucb INC

Rystiggo

Rozanolixizumab-Noli · Subcutaneous · Neonatal Fc Receptor Blocker

NovelPriority reviewOrphan

CDER novel approval, Jun 26, 2023: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive

Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jun 26, 2023

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

22

12 Phase 3, 2 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Rozanolixizumab" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rystiggo (Rozanolixizumab-Noli)

2024 spending

$56.3M

Beneficiaries

279

1,363 claims

Per beneficiary

$201,820

$3,016.15 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$5,879,200
2024$56,307,919

Part B: Rystiggo (Rozanolixizumab-Noli) · HCPCS J9333

2024 spending

$30.7M

Beneficiaries

191

2,104 claims

Per beneficiary

$160,482

2024 ASP limit $22.82 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$30,652,022

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.